Share on StockTwits

Opko Health (NYSE:OPK) CEO Phillip Md Et Al Frost purchased 15,000 shares of Opko Health stock on the open market in a transaction dated Monday, June 23rd. The shares were purchased at an average price of $9.05 per share, for a total transaction of $135,750.00. Following the completion of the transaction, the chief executive officer now directly owns 1,987,500 shares in the company, valued at approximately $17,986,875. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Shares of Opko Health (NYSE:OPK) traded down 1.77% during mid-day trading on Tuesday, hitting $8.89. 1,833,330 shares of the company’s stock traded hands. Opko Health has a 52 week low of $6.75 and a 52 week high of $12.95. The stock has a 50-day moving average of $8.73 and a 200-day moving average of $8.83. The company’s market cap is $3.678 billion.

Opko Health (NYSE:OPK) last issued its quarterly earnings data on Friday, May 9th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by $0.01. The company had revenue of $22.30 million for the quarter, compared to the consensus estimate of $22.77 million. On average, analysts predict that Opko Health will post $-0.38 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on OPK shares. Analysts at TheStreet upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a research note on Friday, May 30th. Finally, analysts at Oppenheimer cut their price target on shares of Opko Health from $13.00 to $12.00 in a research note on Monday, May 12th. They now have an “outperform” rating on the stock. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Opko Health has an average rating of “Buy” and an average target price of $12.50.

OPKO Health, Inc (NYSE:OPK) is a multi-national biopharmaceutical and diagnostics company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.